Research and Development Contract Revenue
The Company had no research and development contract revenue in both the first quarters of fiscal 2009 and 2008.
Cost of sales and margins
Cost of sales totaled $447,000 in the first quarter of fiscal 2009 (2008 - $313,000). Margins, on a percentage basis, in the first quarter of fiscal 2009 were 51.5% (2008 - 58.5%). The decrease in margins reflects higher purchase costs resulting from a lower Canadian dollar versus both the U.S. dollar and the Euro. In addition, some competitive pricing in the current market has also resulted in lower pricing to customers.
Research & development
Research and development costs in the first quarter of fiscal 2009 totaled $1,641,000 (2008 - $782,000) for an increase of $859,000. Higher research and development costs in the first quarter of fiscal 2008 reflect increased costs for both L-DOS47 and Topical Interferon Alpha-2b programs with the latter representing the majority of the research and development expenditures in the quarter. Research and development expenditures were split relatively equally amongst the L-DOS47, LSIL and AGW initiatives, with slightly higher expenditures associated with AGW due to the activities to enhance patient enrollment including the expansion of the trial to open study centers in Germany.
Operating, general & administration
Operating, general and administration expenses in the first quarter of fiscal 2009 totaled $1,310,000 (2008 - $1,313,000), for a decrea
|SOURCE Helix BioPharma Corp.|
Copyright©2008 PR Newswire.
All rights reserved